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ABSTRACT
Objective: Xanthorrhizol is known to have anti-inflammatory activity. However, new xanthorrhizol derivatives with improved anti-inflammatory 
activity and reduced toxicity are needed.
Methods: In this study, the derivatives of xanthorrhizol were synthesized and spectroscopically characterized, and their inhibitory activities against 
nitric oxide (NO) production were evaluated in RAW 264.7 macrophage cells.
Results: The first stage of synthesis produced compounds 2a and 2b in 58.49% and 63.26% yields, respectively. Compounds 2a and 2b were oxidized 
using potassium permanganate, giving compounds 3a and 3b in yields of 51.92% and 43.78%, respectively. Compounds 1, 2a, 3a, and 3b along 
with diclofenac sodium (the positive control) exhibited IC50 values for NO production of 31.82, 73.85, 354.05, 97.19, and 78.43 µM, respectively. In 
contrast, compound 2b did not show any inhibitory activity. Based on cytotoxicity assay, compounds 1, 2a, 2b, 3a, 3b, and diclofenac sodium had LD50 
values of 30.97, 65.15, 31.15, 117.86, 53.40, and 51.67 µM, respectively. The NO inhibitory activities of compounds 2a, 3a, and 3b were lower than that 
of xanthorrhizol (compound 1). However, cytotoxicity tests showed that compounds 2a, 3a, and 3b had reduced toxicities compared to xanthorrhizol.
Conclusion: The modification of xanthorrhizol through esterification and oxidation produced derivative compounds with weaker anti-inflammatory 
activity but reduced cytotoxicity.
Keywords: Xanthorrhizol, Oxidation, Potassium permanganate, Nitric oxide, RAW 264.7 cells.
INTRODUCTION
Inflammation is a protective immune response designed to protect 
against pathogenic infections and tissue injuries [1]. To reduce 
inflammation, nonsteroidal anti-inflammatory drugs (NSAIDs) are 
commonly prescribed. NSAIDs work by inhibiting cyclooxygenase 
(COX) enzymes, which catalyze the conversion of arachidonic acid into 
the inflammatory mediators prostaglandin and thromboxane [2,3]. 
However, NSAIDs, which inhibit the COX-1 enzyme activity, have toxic 
effects on the gastrointestinal tract, especially the stomach, and the 
inhibition of COX-2 enzyme increases cardiovascular risk [4]. Therefore, 
novel anti-inflammatory drugs with different targets are desired.
When developing anti-inflammatory drugs, an alternative to COX 
enzyme inhibition is the hindrance of nitric oxide (NO) production. In 
addition to COX inhibition, some NSAIDs also inhibit NO production 
by restraining inducible NO synthase (iNOS) expression. For example, 
diclofenac sodium, an NSAID, inhibits iNOS gene expression at the 
transcription level by suppressing nuclear factor kappa B activity. The 
inhibition of iNOS gene expression ultimately results in a reduction in 
NO production [5] and NOS inhibitors found to be effective in treating 
experimentally induced arthritis [6].
Xanthorrhizol, a major component of Curcuma xanthorrhiza, is a known 
anti-inflammatory agent [7-10]. The inhibition of NO production by 
xanthorrhizol in RAW 264.7 cells stimulated by lipopolysaccharide 
(LPS) was previously investigated [11]. Xanthorrhizol has been found 
to restrict iNOS and COX expression in the skin of mice with acute 
inflammation under stimulation by 12-O-tetradecanoylphorbol-13-
acetate [7]. Xanthorrhizol derivatization has been carried out through 
modifications to the xanthorrhizol structure, including the conversion of 
hydroxyl groups into ester groups [12,13] and the addition of epoxides 
and diols into the unsaturated chain using a weak oxidizing agent [12]. 
However, a new process to obtain novel derivatives of xanthorrhizol is 
needed to obtain compounds with enhanced anti-inflammatory ability 
and lower toxicity. Potassium permanganate (KMnO4) is an important 
strong oxidizing agent which is very useful for oxidizing carbon-carbon 
double bonds in organic compounds [14]. We have recently reported 
the oxidation of 1-O-acetyl-xanthorrhizol using permanganate to obtain 
an α-hydroxyl ketone of the compound, but the synthesis of other 
derivatives and evaluation of their biological activities have not been 
reported [15].
Herein, we report the synthesis of other derivatives of xanthorrhizol 
and the evaluation of anti-inflammatory activities of all obtained 
derivatives by testing their inhibition of NO production in vitro using 
RAW 264.7 macrophage cells stimulated by LPS.
EXPERIMENTAL METHODS
Materials and instruments
All solvents, chemicals, and reagents were commercially purchased. 
Xanthorrhizol was supplied by Java Plant (Karanganyar, Indonesia). The 
purity of xanthorrhizol was evaluated by thin-layer chromatography 
(TLC) on silica gel 60 F254 plates (Merck). Fourier transform infrared 
(FTIR) spectra were recorded using an FTIR spectrophotometer 
(Nicolet iS10, Thermo Fisher Scientific, Waltham, MA, USA). Nuclear 
magnetic resonance (NMR) spectra were collected using an NMR 
spectrometer (Agilent, Santa Clara, CA, USA) at 500 MHz for protons 
and 125 MHz for carbon atoms with deuterated chloroform (CDCl3) as 
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solvent and tetramethylsilane as an internal standard. High-resolution 
mass spectrometry (HR-MS) was carried out on an LCT Premier XE-
TOF mass spectrometer (Waters Corp., Milford, MA, USA) in positive 
electrospray ionization (ESI) mode.
Chemistry
Synthesis of 2-methyl-5-(6-methylhept-5-en-2-yl)phenyl acetate (2a)
Compound 2a was prepared using the previously reported method 
with slight modification [16,17]. The salt used in this study was dried 
at 90°C before the synthesis. In a boiling flask, xanthorrhizol (5 mmol, 
1091.65 mg) was dissolved in 30 mL ethyl acetate. NaHCO3 (50 mmol, 
4200.35 mg) and acetate anhydride (100 mmol, 10.209 mg) were 
then added and stirred at room temperature for 24 h. The reaction 
was monitored by TLC until the reaction was complete. The formed 
precipitate was filtered, and the filtrate was concentrated. The obtained 
residue was then extracted using dichloromethane (15 mL) and water 
(5 mL). The organic phase was collected and dried by adding Na2SO4. 
Subsequently, the product was concentrated by evaporating the solvent 
using a rotary evaporator. Finally, the product was purified by column 
chromatography using a mixture of hexane and ethyl acetate (9:1 v/v) 
to obtain pure 2a.
Synthesis of 2-methyl-5-(6-methylhept-5-en-2-yl)phenyl benzoate (2b)
Compound 2b was synthesized using a reported method with slight 
modification [16,17]. Xanthorrhizol (1.084 g, 5 mmol) was dissolved in 
10 mL of 5% NaOH at 0°C–5°C. Benzoyl chloride (0.581 mL, 5 mmol) 
was added to the mixture followed by stirring until no benzoyl 
chloride fumes were present. The product was separated using 
dichloromethane and concentrated. The product was then purified by 
column chromatography using a mixture of hexane and ethyl acetate 
(9:1, v/v) to obtain pure 2b.
Synthesis of 5-(6-hydroxy-6-methyl-5-oxoheptan-2-yl)-2-methylphenyl 
acetate (3a)
Compound 3a was prepared according to the procedure reported in our 
previous publication [15].
Synthesis of 5-(6-hydroxy-6-methyl-5-oxoheptan-2-yl)-2-methylphenyl 
benzoate (3b)
Compound 3b was synthesized using a previously reported method[18]. 
Compound 2b (2.206 mmol), glacial acetic acid (4.941 mL), acetone 
(11 mL), and distilled water (3.81 mL) were added to a three-neck 
boiling flask. After conditioning the mixture at 0°C–5°C, KMnO4 crystals 
(2.42 mmol, 386.62 mg) were added slowly for 6 h followed by stirring 
for an additional 1 h. The reaction was monitored until completion 
using TLC. Subsequently, the solution was transferred into 10.83 mL 
of distilled water. H2O2 was then added until a clear solution formed. 
The obtained product was extracted using dichloromethane and then 
purified by column chromatography using a mixture of hexane, ethyl 
acetate, and methanol (8:2:1 v/v/v).
Anti-inflammatory activity
Cell culture
Murine macrophage cells (RAW 264.7, BPPT collection) were cultured 
at 37°C in Roswell Park Memorial Institute medium containing 10% 
fetal bovine serum (FBS) in a humidified incubator with 5% CO2.
Measurement of NO
NO was determined by calculating the quantity of nitrite from sodium 
nitrite in the cell culture medium using Griess reagent as reported 
previously [11,19]. NO inhibition was analyzed in RAW 264.7 cells that 
had been stimulated using LPS. Seeded cells were placed in 96-well 
culture plates at a density of 1×105 cells/well and incubated at 37°C in 
an incubator containing 5% CO2 for 24 h. After incubation, the medium 
was discarded and replaced with various concentrations of each sample 
in serum (2% FBS) for 2 h. LPS was added to each well to achieve a final 
LPS concentration of 1 ppm. The cells were then reincubated for 24 h. 
Cell culture supernatant (75 µL) was mixed with Griess reagent (75 µL) 
in a new 96-well plate in the dark for 20 min. Finally, the absorption was 
measured spectrophotometrically at 540 nm. The NO concentration (A) 
was calculated using a sodium nitrite standard curve, and the inhibition 






Where, B is the NO concentration after treatment.
Cytotoxicity assay against RAW 264.7 macrophage cells
Cytotoxicity of the synthesized compounds on RAW 264.7 
macrophages was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) method [11]. RAW 264.7 cells 
were added to 96-well culture plates at a density of 1×104 cells/well 
and left to attach for 24 h in an incubator at 37°C with 5% CO2. After 
cell growth, the medium was removed and replaced with various 
concentrations of each sample in serum (2% FBS) for 24 h. After 
incubation, the culture medium was discarded, and (MTT: 0.5 mg/mL, 
100 µL) solution was added to each cell. The cells were then reincubated 
at 37°C in an incubator containing 5% CO2 for 4 h. After removing the 
culture supernatants, 200 µL dimethyl sulfoxide was added followed 
by agitation for 10 min in the dark. The absorption at 570 nm (T) was 








Where, C is the absorption of the control. The IC50 value was calculated 
by plotting cell viability against log concentration (logC) of the tested 
compounds using SPSS software.
RESULTS AND DISCUSSION
Chemistry
The synthetic method used to obtain xanthorrhizol derivatives is shown 
in Fig. 1. The hydroxyl groups of xanthorrhizol were first esterified 
either using acetic anhydride with NaHCO3 as a catalyst to give 2a or 
using benzoyl chloride with NaOH as a catalyst to give 2b. Second, the 
oxidation of 2a and 2b using a strong oxidizing agent (KMnO4) in the 
presence of weak acid (acetic acid) at 0°C–5°C and water/acetone as 
solvent gave compounds 3a and 3b.
Spectroscopy data of the synthesized compounds
2-Methyl-5-(6-methylhept-5-en-2-yl)phenyl acetate (2a)
Compound 2a was obtained as a yellow oil in 58.49% yield: FTIR (KBr) 
cm−1, 2964.21 and 2926, 13 (C-H aliphatic), 1768.06 (C=O, ester), 
1214.16 (C–O, ester). 1H-NMR (500 MHz, CDCl3), δ (ppm): 7.14 (1H, d, 
J = 7.8, Ar-H), 6.97 (1H, d, J = 6, Ar-H), 6.81 (1H, s, Ar-H), 5.07 (1H, m, 
CH2-CH=C), 2.67, (1H, m, CH–Ar), 2.31 (3H, s, CH3 acetate), 2.14 (3H, 
s, CH3–Ar), 1.89 (2H, m, CH2–CH2–CH), 1, 66 (3H, s, CH3–C, 1.58 (2H, 
m, CH–CH2–CH2), 1.52 (3H, s, CH3–C), 1, 22 (3H, d, J = 1.39, CH3–CH), 
13C-NMR (500 MHz, CDCl3) δ/ppm: 169.35 (C=O acetate), 149.42 (C-O 
acetate), 147.07 (CAr), 131.65 (CH=C–(CH3)2 aliphatic), 130.9 (CAr), 
127.31 (CAr), 124.85 (CAr), 124.51 (CH2–CH=C), 120.47 (CAr), 38.99 
(CH–Ar), 38.48 (CH–CH2–CH2), 26.21 (CH2–CH2–CH), 25.85 (CH3–C), 
22.30 (CH3–CH), 20.97 (CH3–acetate), 17.81 (CH3–C), 15.93 (CH3–Ar). 
HR ESI-MS m/z: 283.1680 [M+Na]+ calculated for C17H24O2Na: 283.1674.
2-Methyl-5-(6-methylhept-5-en-2-yl)phenyl benzoate (2b)
Compound 2b was obtained as a yellow oil in 63.2% yield: FTIR (KBr) 
cm−1, 2962.75 and 2924.22 (C–H aliphatic), 1737.90 (C=O ester), 
1263.59 (C–O ester). 1H-NMR (500 MHz, CDCl3), δ (ppm): 8.23 (1H, d, 
J = 8.55, Ar-H), 7.52 (1H, m, Ar-H), 7.64 (1H, m, Ar-H), 7.18 (1H, d, J = 7.8, 
Ar-H), 7.02 (1H, d, J = 7.75, Ar-H), 6.96 (1H, s, Ar-H), 5.09 (1H, m, CH2–
CH=C), 2.7 (1H, m, CH–Ar), 2.19 (3H, s, CH3–Ar), 1.92 (2H, m, CH2–CH2–
CH), 1.67 (3H, s, CH3–C), 1.6 (2H, m, CH–CH2–CH2), 1.54 (3H, s, CH3–C), 
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1.25 (3H, d, J = 6.9 CH3–CH), 13C-NMR (500 MHz, CDCl3) δ (ppm): 164.97 
(C=O), 149.61 (C–O), 147.13 (CAr), 133.61 (CAr), 131.65 (CH=C–(CH3)2, 
131.02 (CAr), 130.28 (CAr), 129.8 (CAr), 128.71 (CAr), 127.53 (CAr), 
124.88 (CAr), 124.54 (CH2–CH=C), 120.61 (CAr), 39.05 (CH–Ar), 38.51 
(CH–CH2–CH2), 26.24 (CH2–CH–CH), 25.86 (CH3–C), 22.35 (CH3–CH), 
17.83 (CH3–C), 16.04 (CH3–Ar), HR ESI-MS m/z: 345.1827 [M+Na]+ 
calculated for C22H26O2Na: 345.1831.
5-(6-Hydroxy-6-methyl-5-oxoheptan-2-yl)-2-methylphenyl acetate (3a)
The spectroscopic data of compound 3a were reported previously [15].
5-(6-Hydroxy-6-methyl-5-oxoheptan-2-yl)-2-methylphenyl benzoate (3b)
Compound 3b was obtained as a yellow oil in 43.78% yield: FTIR (KBr) 
cm−1, 3492.04 (O–H), 2969.65 and 2929.93 (C–H aliphatic), 1736.23 
(C=O ester), 1710.52 (C=O ketone), 1266.26 (C–O ester), 1H-NMR (500 
MHz, CDCl3), δ (ppm): 8.21 (2H, d, J = 6.55, Ar-H), 7.52 (2H, m, Ar-H), 
7.65 (1H, m, Ar-H), 7.2 (1H, d, J = 7.8, Ar-H), 7 (1H, d, J = 6,1, Ar-H), 
6.93 (1H, s, Ar-H), 3.74 (1H, s, –OH), 2.71 (1H, m, CH–Ar), 2.2 (3H, s, CH3–
Ar), 2.4 (2H, m, CH2–CH2–C=O), 1.29 (3H, s, CH3–C), 1.96 and 1.87 (2H, m, 
CH–CH2–CH2), 1.29 (3H, s, CH3–C), 1.28 (3H, d, J = 7, 1, CH3–CH), 13C-NMR 
(500 MHz, CDCl3) δ (ppm): 214.69 (C=O ketone), 165.09 (C=O benzoyl), 
149.72 (C–O benzoyl), 145.46 (CAr), 133.73 (CAr), 131.36 (CAr), 130.27 
(CAr), 129.66 (CAr), 128.75 (CAr), 128.17 (CAr), 124.77 (CAr), 120.78 
(CAr), 38.93 (CH–Ar), 31.83 (CH–CH2–CH2), 33.62 (CH2–CH2–C=O), 26.57 
(CH3–C), 26.7 (CH3–C) 22.73 (CH3–CH), 16.03 (CH3–Ar), HR ESI-MS m/z: 
377.1718 [M+Na]+ calculated for C22H26O4Na: 345.1729.
The FTIR spectra of 2a and 2b show bands corresponding to C=O in 
ester groups at 1768.06 and 1737.9 cm−1, respectively. No bands of–
OH groups (expected at 3400 cm−1) are observed, indicating that the 
hydroxyl groups were all replaced by ester groups. This conclusion is 
supported by the 12C-NMR spectra, in which the signals of the carbon 
atoms in the ester groups are observed at 169.35 and 164.97 ppm for 
2a and 2b, respectively.
The FTIR spectra of 3a and 3b show peaks corresponding to–OH 
groups at 3482.04 and 3492.04 cm−1, respectively. Ketone groups are 
also indicated by the peaks at 1709.98 and 1710.52 cm−1 in the spectra 
of 3a and 3b, respectively. The previously formed ester groups (in 2a 
and 2b) remained in 3a and 3b. The FTIR results were supported by 
the 13C-NMR spectra of 3a and 3b, in which the peaks corresponding to 
the carbon atoms of ketone groups are found at 214.5 and 214.69 ppm, 
respectively, and the peaks of the carbon atoms of–OH groups are 
located at 76.33 and 76.36 ppm, respectively. The 1H-NMR and HR-MS 
data also supported the reported structures of all compounds.
Inhibition of NO production
The inhibition of NO production by the synthesized products was 
evaluated in RAW 264.7 monocyte macrophage-like cells from BALB/c 
mice induced by Abelson leukemia virus. These cells have the ability to 
undergo pinocytosis and phagocytosis [20]. LPS, the main component 
of the bacterial cell wall, was used to stimulate NO production in 
the cells [21]. The NO inhibition assay indicated IC50 values for NO 
production of 73.85, 354.05, and 97.19 µM for compounds 2a, 3a, and 
3b, respectively. In contrast, 2b did not inhibit NO production (Table 1). 
The IC50 values obtained for xanthorrhizol (1) and diclofenac sodium 
were 31.82 and 78.43 µM, respectively. Thus, 2a, 3a, and 3b had lower 
inhibitory activities for NO production compared to 1.
Based on cytotoxicity assay, the LD50 values of compounds 2a, 2b, 3a, 
and 3b were 65.15, 31.15, 117.86, and 53.40 µM, respectively (Table 1). 
The LD50 values of compounds 1 and diclofenac sodium were 30.97 
and 51.67 µM, respectively (Table 1). Thus, the cytotoxicities of the 
xanthorrhizol derivatives 2a, 2b, 3a, and 3b were lower than that of 1. 
These results indicate that all structural modifications of xanthorrhizol 
reduced the cytotoxicity. Xanthorrhizol has potential as an anti-
inflammatory agent, but it also was reported to have a high cytotoxic 
potential [7-10]. Further studies should be done to explore the relation 
of its pharmacological activity and cytotoxicity.
CONCLUSION
Ester derivatives of xanthorrhizol and its oxidation products were 
successfully synthesized. Compounds 2a and 2b were generated in 
yields of 58.49% and 63.26%, respectively, through the esterification 
of the hydroxyl groups of xanthorrhizol. Compounds 3a and 3b were 
produced in yields of 51.92% and 43.78%, respectively, by oxidizing 2a 
and 2b with KMnO4 to break the double bonds in the alkyl groups. The 
anti-inflammatory activities of the products were tested by NO inhibition 
assay using RAW 264.7 macrophage cells. The results indicated that 
the xanthorrhizol derivatives were less active against NO production 
compared to xanthorrhizol. However, cytotoxicity assay revealed that 
the modification of xanthorrhizol successfully reduced its toxicity.
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Table 1: Cytotoxicities and inhibitory activities for NO production 
of different compounds in RAW 264.7 cells induced by LPS






Diclofenac sodium 78.43 51.67
1NO production inhibition, 2Cytotoxicity. NO: Nitric oxide, 
LPS: Lipopolysaccharide
Fig. 1: Structures and synthetic routes of xanthorrhizol derivatives. Reaction conditions: (i) Acetic anhydride NaHCO3 ethyl acetate, rt; 
(ii) benzoyl chloride, NaOH, cold (0°C–5°C); and (iii) KMnO4, acetic acid, acetone, water, 0°C–5°C
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